Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
J Food Biochem. 2021 Apr;45(4):e13710. doi: 10.1111/jfbc.13710. Epub 2021 Mar 22.
The pathophysiology of chemotherapy-associated anemia, prevalent in at least 75% of patients, remains difficult to establish. Chemotherapy-related anemia is attributed in part to eryptosis, and it is therefore of considerable interest to interrogate the toxicity of investigative anticancer compounds to red blood cells (RBCs). Beta-lapachone (LAP), an anthraquinone extracted from the bark of Lapacho tree (Tabebuia avellanedae), is effective against a myriad of cancer cells. However, the toxicity of LAP to RBCs remains unexplored. Hemoglobin leakage as a surrogate for hemolysis was photometrically measured, while flow cytometry was employed to capture phosphatidylserine (PS) exposure with Annexin-V-FITC, calcium levels with Fluo4/AM, cell size by forward scatter (FSC), and oxidative stress by H2DCFDA. Our results show that LAP, at antitumor levels (10-30 µM), induces dose-dependent hemolysis secondary to calcium influx from the extracellular space. Moreover, LAP stimulates eryptosis, as evident from PS exposure, which is associated with reduced cell volume and intracellular calcium overload. Importantly, it is also revealed that the cytotoxicity of LAP is mediated through casein kinase 1α. Altogether, this report shows, for the first time, that LAP possesses both hemolytic and eryptotic potential against RBCs that necessitates careful application in chemotherapy. PRACTICAL APPLICATIONS: Lapacho is a widely consumed herbal tea with origins in the Tabebuia avellanedae tree endogenous to South America. LAP is one of the active ingredients in lapacho with promising antitumor potential. We show that LAP is cytotoxic to human RBCs by virtue of eryptosis and hemolysis, and we identify associated molecular mechanisms. Given that these two manifestations are known to contribute to chemotherapy-induced anemia, our study provides invaluable insights into the suitability of LAP in cancer management and sheds some light on possible strategies to limit its undesirable side effects.
化疗相关性贫血的病理生理学,在至少 75%的患者中普遍存在,仍然难以确定。化疗相关性贫血部分归因于红细胞的溶血,因此,研究抗癌化合物对红细胞(RBC)的毒性具有重要意义。β-拉帕醌(LAP)是从拉帕乔树(Tabebuia avellanedae)树皮中提取的蒽醌,对多种癌细胞有效。然而,LAP 对 RBC 的毒性仍未得到探索。血红蛋白渗漏作为溶血的替代物通过比色法测量,同时使用流式细胞术结合 Annexin-V-FITC 捕获磷脂酰丝氨酸(PS)暴露、Fluo4/AM 检测钙水平、前向散射(FSC)测量细胞大小以及 H2DCFDA 检测氧化应激。我们的结果表明,LAP 在抗肿瘤水平(10-30 μM)下,通过细胞外钙内流诱导剂量依赖性溶血。此外,LAP 刺激红细胞溶血,这从 PS 暴露中可见,这与细胞体积减小和细胞内钙超载有关。重要的是,还揭示了 LAP 的细胞毒性是通过酪蛋白激酶 1α 介导的。总之,本报告首次表明,LAP 对 RBC 具有溶血和溶血作用,这在化疗中需要谨慎应用。实际应用:拉帕乔是一种广泛消费的草药茶,起源于南美洲特有的 Tabebuia avellanedae 树。LAP 是拉帕乔的一种有效成分,具有有前途的抗肿瘤潜力。我们表明,LAP 通过溶血和溶血作用对人 RBC 具有细胞毒性,并确定了相关的分子机制。鉴于这两种表现已知会导致化疗相关性贫血,我们的研究为 LAP 在癌症管理中的适用性提供了宝贵的见解,并为限制其不良副作用的可能策略提供了一些思路。